AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10463751 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant osteogenic protein (OP-1) on a collagen type-I carrier
Number of subjects: 24
Study 10463751 — intervention group
Group type: COMPARATOR
Intervention: collagen type-I alone
Number of subjects: 24
Study 10463751 — intervention group
Group type: COMPARATOR
Intervention: demineralised bone
Number of subjects: 24
Study 10463751 — intervention group
Group type: COMPARATOR
Intervention: untreated group
Number of subjects: 24
Study 7541064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine combination therapy for 2 years
Number of subjects: 35
Study 7541064 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient HIV suppression
Number of subjects: 35
Study 7541064 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine resistance
Number of subjects: 35
Study 7541064 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 35
Study 7541064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in > or = 4 patients each
Number of subjects: 35
Study 2355814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 500 mg
Number of subjects: 27
Study 2355814 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo (Pla)
Number of subjects: 27
Study 2355814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) during acute hypoxia
Number of subjects: 27
Study 2355814 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo (Pla) during acute hypoxia
Number of subjects: 27
Study 30590606 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative therapy with capecitabine and oxaliplatin
Number of subjects: 150
Study 30590606 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 150
Study 29901635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin treatment
Number of subjects: 0
Study 29901635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 25394608 — intervention group
Group type: EXPERIMENTAL
Intervention: Group lifestyle intervention (educational intervention)
Number of subjects: 60
Study 25394608 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine prenatal care)
Number of subjects: 60
Study 24793669 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (one 5‐minute inflation of a blood pressure cuff to 200 mm Hg around the upper arm)
Number of subjects: 94
Study 24793669 — intervention group
Group type: COMPARATOR
Intervention: Control (no remote ischemic preconditioning)
Number of subjects: 94
Study 23131285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation + Continuous blood purification (CBP) with bicarbonate
Number of subjects: 26
Study 23131285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation + Continuous blood purification (CBP) with lactate
Number of subjects: 26
Study 23131285 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (control group)
Number of subjects: 26
Study 20500533 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to drug (> 80% of days covered)
Number of subjects: 0
Study 20500533 — intervention group
Group type: COMPARATOR
Intervention: Low adherence to drug (< 50% of days covered)
Number of subjects: 0
Study 18559019 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Breast Cancer: A Booklet for Breast-Care Nurses
Number of subjects: 92
Study 18559019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 92
Study 15821182 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30
Study 15821182 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (control)
Number of subjects: 30
Study 12365468 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of metformin
Number of subjects: 90
Study 12365468 — intervention group
Group type: COMPARATOR
Intervention: Insulin only (Control)
Number of subjects: 90
Study 10585981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of Adderall received in the morning only
Number of subjects: 21
Study 10585981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of MPH received twice (7:30 AM and 11:30 AM) with 0.15 mg/kg received at 3:30 PM
Number of subjects: 21
Study 10585981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of MPH at 3:30 PM
Number of subjects: 21
Study 10585981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10585981 — intervention group
Group type: COMPARATOR
Intervention: Adderall in the morning and placebo at 3:30 PM
Number of subjects: 21
Study 8721804 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 7788
Study 8721804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7788
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 3.2 mg/m2/24 hr with 66 Gy in 33 fractions over 6 1/2 weeks for NSCLC
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 4.0 mg/m2/24 hr with 45 Gy in 25 fractions over 5 weeks for rectal carcinoma
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 5.0 mg/m2/24 hr
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative electron boost
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Further external beam therapy up to 59.4 Gy
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: No further therapy
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity related to cisplatin dose
Number of subjects: 31
Study 1846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tolerated dose
Number of subjects: 31
Study 6194934 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (A)
Number of subjects: 26
Study 6194934 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch (H)
Number of subjects: 26
Study 6194934 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (S)
Number of subjects: 26
Study 31492016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month breast milk sCD14 levels in the atopic dermatitis (AD) group
Number of subjects: 258
Study 31492016 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month breast milk sCD14 levels
Number of subjects: 258
Study 29273077 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training intervention for frontline officers
Number of subjects: 0
Study 29273077 — intervention group
Group type: COMPARATOR
Intervention: Routine training
Number of subjects: 0
Study 27040515 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP tertile 1 (BNP ≤ 376 pg/mL)
Number of subjects: 251
Study 27040515 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP tertile 2 (BNP 377 to 792 pg/mL)
Number of subjects: 251
Study 27040515 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP tertile 3 (BNP ≥ 793 pg/mL)
Number of subjects: 251
Study 27040515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic markers measured via pulmonary artery catheter
Number of subjects: 251
Study 24339313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygienic care program (OHCP) including tooth brushing with an inter-dental brush and tongue cleaner, and cleaning with chlorhexidine, administered once per day for a mean duration of 2.2 weeks.
Number of subjects: 56
Study 24339313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OHCP).
Number of subjects: 56
Study 21288666 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg DM Se
Number of subjects: 119
Study 21288666 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg DM Se
Number of subjects: 119
Study 21288666 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg DM Se
Number of subjects: 119
Study 21288666 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg DM Se (Control)
Number of subjects: 119
Study 21288666 — intervention group
Group type: COMPARATOR
Intervention: Se-deficient (Group 1)
Number of subjects: 119
Study 21288666 — intervention group
Group type: COMPARATOR
Intervention: Se-excess (Group 4)
Number of subjects: 119
Study 19730959 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 31
Study 19730959 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 31
Study 17503747 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction/maintenance (IM) therapy: two NRTIs + one NNRTI + one protease inhibitor for 24-32 weeks, followed by two NRTIs + NNRTI
Number of subjects: 122
Study 17503747 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST): two NRTIs + NNRTI
Number of subjects: 122
Study 17503747 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction/maintenance (IM) therapy
Number of subjects: 122
Study 17503747 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 122
Study 15201565 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, flexible)
Number of subjects: 168
Study 15201565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 11584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Active abdominal generator position
Number of subjects: 25
Study 11584456 — intervention group
Group type: COMPARATOR
Intervention: Active pectoral generator position
Number of subjects: 25
Study 9554347 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil (500 microg)
Number of subjects: 234
Study 9554347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2,000 microg)
Number of subjects: 234
Study 9554347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9554347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil-prazosin combination (500/2,000 microg)
Number of subjects: 234
Study 9554347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (125 microg)
Number of subjects: 234
Study 9554347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil (250 microg)
Number of subjects: 234
Study 7988256 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (lobectomy, pneumonectomy, other procedures)
Number of subjects: 783
Study 7988256 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 783
Study 7988256 — intervention group
Group type: COMPARATOR
Intervention: Pneumonectomy
Number of subjects: 783
Study 7988256 — intervention group
Group type: COMPARATOR
Intervention: Simple resection
Number of subjects: 783
Study 7988256 — intervention group
Group type: COMPARATOR
Intervention: Extended resection
Number of subjects: 783
Study 7988256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients age 60 or older
Number of subjects: 783
Study 7988256 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 783
Study 7988256 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Karnofsky index < 90
Number of subjects: 783
Study 2536538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 42
Study 2536538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion
Number of subjects: 42
Study 29344729 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation (0.3 g kg bm-1)
Number of subjects: 11
Study 29344729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride, 0.21 g kg bm-1)
Number of subjects: 11
Study 27315514 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DCS administered 1 hr prior to the final three sessions of CBT
Number of subjects: 180
Study 27315514 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo administered 1 hr prior to the final three sessions of CBT
Number of subjects: 180
Study 25661281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg once-daily
Number of subjects: 94
Study 25661281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg twice-daily
Number of subjects: 94
Study 25661281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (both dosing regimens)
Number of subjects: 94
Study 25661281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 23161599 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (mean dose: 14.00 mg)
Number of subjects: 59
Study 23161599 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (mean dose: 52.50 mg)
Number of subjects: 59
Study 23161599 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based incentives for attendance and completion of study assessments
Number of subjects: 59
Study 23161599 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating voucher incentives for drug-free urine samples (MOTHER-trial only)
Number of subjects: 59
Study 23161599 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine solution for neonatal abstinence syndrome treatment
Number of subjects: 59
Study 21903536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system with diamond bur preparation
Number of subjects: 0
Study 21903536 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system with Er:YAG laser preparation
Number of subjects: 0
Study 21903536 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive system with diamond bur preparation
Number of subjects: 0
Study 21903536 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive system with Er:YAG laser preparation
Number of subjects: 0
Study 18353012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-controlled Er:YAG laser at threshold levels 9 and 10 [U]
Number of subjects: 26
Study 18353012 — intervention group
Group type: COMPARATOR
Intervention: Conventional bur treatment
Number of subjects: 26
Study 18353012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-controlled Er:YAG laser
Number of subjects: 26
Study 16115991 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine + ketamine (n = 8)
Number of subjects: 24
Study 16115991 — intervention group
Group type: COMPARATOR
Intervention: placebo + ketamine (n = 8)
Number of subjects: 24
Study 16115991 — intervention group
Group type: COMPARATOR
Intervention: morphine + placebo (n = 8)
Number of subjects: 24
Study 12693594 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine culture
Number of subjects: 1661
Study 12693594 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine microscopy
Number of subjects: 1661
Study 12693594 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic sensitivity testing
Number of subjects: 1661
Study 10373809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced, distance education package on violence against women (8 weeks duration, 7 modules including written and audio material, mentor and teleconference support)
Number of subjects: 60
Study 7472824 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 139
Study 2137066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil (250 mg day-1)
Number of subjects: 21
Study 2137066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2137066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbinil
Number of subjects: 21
Study 2137066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 7011622 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/24 hr frusemide (sustained)
Number of subjects: 58
Study 7011622 — intervention group
Group type: COMPARATOR
Intervention: 1 g frusemide (single injection)
Number of subjects: 58
Study 31826009 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous acupuncture (PA)
Number of subjects: 21
Study 31826009 — intervention group
Group type: COMPARATOR
Intervention: Original acupuncture (OA)
Number of subjects: 21
Study 28323139 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation + Progressive strength training (PST)
Number of subjects: 72
Study 28323139 — intervention group
Group type: COMPARATOR
Intervention: Physical rehabilitation
Number of subjects: 72
Study 28323139 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-induced inflammation
Number of subjects: 72
Study 25938629 — intervention group
Group type: COMPARATOR
Intervention: MET only (BRIEF)
Number of subjects: 75
Study 25938629 — intervention group
Group type: EXPERIMENTAL
Intervention: THERAPIST (MET/CBT/CM)
Number of subjects: 75
Study 25938629 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPUTER (MET/CBT/CM)
Number of subjects: 75
Study 23369645 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxycodone
Number of subjects: 23
Study 23369645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco smoking (40% ever smoked, 17% current use)
Number of subjects: 3770
Study 21353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of waterpipe use
Number of subjects: 3770
Study 19950571 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 305
Study 18056333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 18056333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear imaging (gated myocardial perfusion SPECT with phase analysis)
Number of subjects: 0
Study 18056333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear imaging (SPECT)
Number of subjects: 0
Study 18056333 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear imaging (PET)
Number of subjects: 0
Study 14729881 — intervention group
Group type: EXPERIMENTAL
Intervention: MBvO gymnastics twice weekly (MBvO2; n = 68)
Number of subjects: 386
Study 14729881 — intervention group
Group type: EXPERIMENTAL
Intervention: MBvO gymnastics once weekly (MBvO1; n = 125)
Number of subjects: 386
Study 14729881 — intervention group
Group type: COMPARATOR
Intervention: Health education programme (Control; n = 193)
Number of subjects: 386
Study 11854673 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior crown margins
Number of subjects: 240
Study 11854673 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor oral hygiene before treatment
Number of subjects: 240
Study 11854673 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque accumulation
Number of subjects: 240
Study 11854673 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of crown margins
Number of subjects: 240
Study 11854673 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of alloy
Number of subjects: 240
Study 9647679 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor analysis of 10 measures from 9 lateralized tasks
Number of subjects: 290
Study 9647679 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction and oblique rotation of five factors
Number of subjects: 290
Study 9647679 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal-components analysis
Number of subjects: 290
Study 9647679 — intervention group
Group type: EXPERIMENTAL
Intervention: Local structure analysis
Number of subjects: 290
Study 7926910 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) 1.5 g/d, slow release tablets
Number of subjects: 40
Study 7926910 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA) 1.5 g/d, slow release tablets
Number of subjects: 40
Study 3135011 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell pertussis vaccine (3 doses, one month apart)
Number of subjects: 1140
Study 3135011 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 1140
Study 3135011 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell pertussis vaccine
Number of subjects: 1140
Study 31305450 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl-based intravenous patient-controlled analgesia with low dose of ketamine (fk-IVPCA)
Number of subjects: 70
Study 31305450 — intervention group
Group type: COMPARATOR
Intervention: thoracic patient-controlled epidural analgesia (t-PCEA)
Number of subjects: 70
Study 27811630 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorado needle
Number of subjects: 101
Study 27811630 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 101
Study 24107877 — intervention group
Group type: EXPERIMENTAL
Intervention: noojerone (memantine) in addition to standard therapy for 6 months
Number of subjects: 45
Study 24107877 — intervention group
Group type: COMPARATOR
Intervention: standard therapy only
Number of subjects: 45
Study 21669163 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 60
Study 21669163 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 19848371 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized aspheric transition zone algorithm (OATz group)
Number of subjects: 23
Study 19848371 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided optimized path difference custom aspheric treatment (OPDCAT group)
Number of subjects: 23
Study 19848371 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 23
Study 17006746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 mcg)
Number of subjects: 44
Study 17006746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 17006746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 44
Study 12735584 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction
Number of subjects: 100
Study 12735584 — intervention group
Group type: COMPARATOR
Intervention: Water Seal
Number of subjects: 100
Study 12735584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10702171 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation during hemodialysis
Number of subjects: 17
Study 10702171 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation after 3 months
Number of subjects: 17
Study 10702171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acid supplementation)
Number of subjects: 17
Study 9357360 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures with informational messages
Number of subjects: 0
Study 9357360 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochures with emotional messages
Number of subjects: 0